# US 2012/0252026 A1 · Cancer biomarker, diagnostic methods, and assay reagents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252026 A1
- Document ID: US20120252026A1
- Status: Published application
- Kind: A1
- Application number: 13/437,484
- Filed: 2012-04-02
- Published: 2012-10-04
- Earliest claimed: 2011-04-01
- Inventors: REUBEN S. HARRIS; Michael Burns; Eric W. Refsland
- Web page: https://patentgrep.com/patent/US20120252026A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 2600/158: Expression markers
- Y10T 428/13: Hollow or container type article [e.g., tube, vase, etc.]
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

This disclosure describes APOBEC3B as a biomarker for certain cancers such as, for example, breast cancer. This disclosure therefore describes methods for detecting APOBEC3B in a biological sample. The methods generally include measuring expression of APOBEC3B in a biological sample obtained from a patient and identifying the patient as having or at risk for having cancer if the measured expression of APOBEC3B is greater than a predetermined reference level of expression. This disclosure also describes isolated polynucleotides that may be used as reagents in methods for detecting and/or measuring APOBEC3B expression.

## Claims

### Claim 1

A method comprising:
measuring expression of APOBEC3B in a biological sample obtained from a patient; and
identifying the patient as having or at risk for having cancer if the measured expression of APOBEC3B is greater than a predetermined reference level of expression.

### Claim 2 (depends on 1)

The method of claim 1 wherein the predetermined reference level of expression comprises the level of APOBEC3B expression in a normal cell.

### Claim 3 (depends on 1)

The method of claim 1 wherein the cancer comprises breast cancer.

### Claim 4 (depends on 1)

The method of claim 1 wherein measuring expression of APOBEC3B comprises quantitative PCR.

### Claim 5 (depends on 4)

The method of claim 4 wherein the quantitative PCR comprises annealing a polynucleotide from the biological sample with at least one primer that comprises the nucleotide sequence of SEQ ID NO:12 or the nucleotide sequence of SEQ ID NO:24.

### Claim 6 (depends on 5)

The method of claim 5 wherein the quantitative PCR comprises:
annealing a polynucleotide from the biological sample with the nucleotide sequence of SEQ ID NO:12; and
annealing a polynucleotide from the biological sample with the nucleotide sequence of SEQ ID NO:24.

### Claim 7

An isolated polynucleotide comprising the nucleotide sequence of SEQ ID NO:12.

### Claim 8

An isolated polynucleotide comprising the nucleotide sequence of SEQ ID NO:24.

### Claim 9

A kit comprising in separate containers:
a first primer that anneals to a first strand of a polynucleotide that encodes APOBEC3B; and
a second primer that anneals to a second strand of a polynucleotide that encodes APOBEC3B.

### Claim 10 (depends on 9)

The kit of claim 9 wherein the first primer comprises the nucleotide sequence of SEQ ID NO:12 and the second primer comprises the nucleotide sequence of SEQ ID NO:24.

### Claim 11 (depends on 9)

The kit of claim 9 further comprising in a separate container a probe that anneals to a nucleotide sequence amplified by polymerase chain reaction using the first primer and the second primer.

### Claim 12 (depends on 11)

The kit of claim 11 wherein the probe comprises the nucleotide sequence of SEQ ID NO:36.

### Claim 13

A method comprising:
measuring expression of APOBEC3B in a biological sample obtained from a patient; and
determining a therapeutic parameter if the measured expression of APOBEC3B is greater than a predetermined reference level of expression, wherein the therapeutic parameter comprises a probability of outcome, likelihood of recurrence, likelihood of therapy resistance, or any combination thereof.

### Claim 14 (depends on 13)

The method of claim 13 wherein the predetermined reference level of expression comprises the level of APOBEC3B expression in a normal cell.

### Claim 15 (depends on 13)

The method of claim 13 wherein measuring expression of APOBEC3B comprises quantitative PCR.

### Claim 16 (depends on 15)

The method of claim 15 wherein the quantitative PCR comprises annealing a polynucleotide from the biological sample with at least one primer that comprises the nucleotide sequence of SEQ ID NO:12 or the nucleotide sequence of SEQ ID NO:24.

### Claim 17 (depends on 16)

The method of claim 16 wherein the quantitative PCR comprises:
annealing a polynucleotide from the biological sample with the nucleotide sequence of SEQ ID NO:12; and
annealing a polynucleotide from the biological sample with the nucleotide sequence of SEQ ID NO:24.
